- MAFLD: How is it different from NAFLD?
-
Gofton C, Upendran Y, Zheng MH, George J
- KMID: 2539787
- Clin Mol Hepatol.
- 2023 Feb;29(Suppl):S17-S31.
- doi: 10.3350/cmh.2022.0367
“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver... -
- CITED
-
- Close
- SHARE
-
- Close
- Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
-
Crane H, Eslick GD, Gofton C, Shaikh A, Cholankeril G, Cheah M, Zhong JH, Svegliati-Baroni G, Vitale A, Kim BK, Ahn SH, Kim MN, Strasser SI, George J
- KMID: 2557394
- Clin Mol Hepatol.
- 2024 Jul;30(3):436-448.
- doi: 10.3350/cmh.2024.0109
Background/Aims: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis... -
- CITED
-
- Close
- SHARE
-
- Close
